REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonist, in Heart Failure Patients With Elevated Pulmonary Capillary Wedge Pressure
This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication for right heart catheterization (RHC). The aim of the study is to evaluate the safety and tolerability of the study drug.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Note: Group A has stopped enrolling and Group B will not enroll participants
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chisinau, Moldova, 2025
- ARENSIA Exploratory Medicine at the Republican Clinical Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Body mass index (BMI) between 18 and 35 kg/m^2, inclusive, rounded to the nearest whole number
- Ambulatory participants with New York Heart Association (NYHA) class II/III heart failure and at least 1 sign and/or symptom of congestion (eg, dyspnea on exertion, worsening edema, orthopnea, etc.)
- Left ventricular ejection fraction (LVEF) ≥20 % and <50% on echocardiogram (ie, HFrEF participants) within 90 days prior to randomization (only for HFrEF participants in Group A and Group B).
- Participants who, in the opinion of the investigator, require a right heart catheterization (not applicable for HFrEF patients not taking sacubitril/valsartan [Group A]).
- Left ventricular ejection fraction (LVEF) ≥50% on echocardiogram (ie, HFpEF participants) within 90 days prior to randomization (only for HFpEF participants in Group C)
- NT-proBNP >1000 pg/mL or Brain Natriuretic Peptide (active form) (BNP) >300 pg/mL as described in the protocol within 30 days prior to randomization measured by the local laboratory (only for HFrEF participants [Group A and Group B]).
- Pulmonary capillary wedge pressure (PCWP) ≥15 mmHg and right artrial pressure (RAP) >5 mmHg on right heart catheterization (RHC) the morning of anticipated study drug dose administration (not applicable for HFrEF participants not taking sacubitril/valsartan [Group A] as described in the protocol).
- Systolic blood pressure (SBP) ≥110 mmHg at the screening visit and on day -1
- Hematocrit >30% at the screening visit and day -1
Key Exclusion Criteria:
- Currently taking IV vasodilators and/or inotropes
- Taking sacubitril/valsartan (only for HFrEF and HFpEF participants not taking sacubitril/valsartan [Group A and Group C, respectively])
- Taking a phosphodiesterase (PDE) inhibitor (eg, sildenafil), or a soluble guanylate cyclase stimulator (SGCS; ie, vericiguat) within 2 weeks of the screening visit or planning on taking valsartan/sacubitril, a PDE inhibitor, or a SGCS at any point during the study
- More than moderate valvular regurgitation/stenosis (ie, moderate-to-severe or severe) on echocardiogram within 90 days prior to randomization
- Known infiltrative or hypertrophic cardiomyopathy
- Acute coronary syndrome within prior 6 months of randomization
- History of cardiac arrest
- Cardiac surgery within 3 months of randomization
- Pacemaker or defibrillator placement within prior 30 days of randomization
- Severe chronic obstructive pulmonary disease (COPD) (defined as Forced Expiratory Volume in 1st second [FEV1] <50% of predicted or Global Initiative for Chronic Obstructive Lung Disease [GOLD] 3 or 4)
- Pulmonary arterial hypertension (World Health Organization [WHO] Group 1) and any medical history at any time of more than moderate pulmonary hypertension (ie, moderate-to-severe, or severe pulmonary hypertension, as described in the protocol
- Congenital heart disease (repaired or unrepaired)
- Inability to lie flat for cardiac catheterization
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group A
Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan |
Single dose administered via IV infusion Single dose administered via IV infusion |
|
Experimental: Group B
Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan |
Single dose administered via IV infusion Single dose administered via IV infusion |
|
Experimental: Group C
Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan |
Single dose administered via IV infusion Single dose administered via IV infusion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: From first dose (Day 1) up to end of study (Day 126)
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as those adverse events with either initial onset after study drug dose or that represented an exacerbation of a pre-existing condition after the study drug dose. |
From first dose (Day 1) up to end of study (Day 126)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP)
Time Frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
|
PCWP was collected during the right heart catheterization on Day 1. |
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
|
|
Change From Baseline in Central Venous Pressure (CVP)
Time Frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
CVP was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CVP was not captured. |
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
|
Change From Baseline in Invasive Cardiac Output (CO)
Time Frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
CO was collected during the right heart catheterization on day 1. For Group A 10mg cohort, the bedside monitor at the site was not compatible with the invasive hemodynamic measurement device, therefore CO was not captured. |
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
|
Change From Baseline in Systemic Vascular Resistance (SVR)
Time Frame: Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
|
SVR was derived as follows: [(Mean Arterial Pressure-Central Venous Pressure)*80]/ Invasive Cardiac Output. For the Group A: 10 mg cohort, the site's bedside monitor was not compatible with the invasive hemodynamic measurement device. As a result, CVP was not captured, and SVR could not be calculated due to the missing CVP data. |
Baseline, Day 1 (0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours post end of infusion)
|
|
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)
Time Frame: Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
mPAP was collected during the right heart catheterization on day 1. |
Baseline, Day 1 (0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, and 6-7 hours post start of infusion)
|
|
Change From Baseline in Pulmonary Vascular Resistance (PVR)
Time Frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
|
Pulmonary Vascular Resistance was derived as follows: [(Mean Pulmonary Artery Pressure-Pulmonary Capillary Wedge Pressure)*80]/ Invasive Cardiac Output. |
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion)
|
|
Change From Baseline in Systolic Blood Pressure (SBP)
Time Frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing right heart catheterization (RHC). |
Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
|
Change From Baseline in Diastolic Blood Pressure (DBP)
Time Frame: Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
For participants enrolled in Group A cohorts, blood pressure was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC. |
Baseline, Day 1 (0, 1, 2, 3, 4, 5, 6, 7, 8 hours post end of infusion), Day 2 to Day 5 every 8 hours, Day 6 first 8 hours, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
|
Change From Baseline in Mean Arterial Pressure (MAP)
Time Frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
MAP was derived as follows: (1/3*SBP + 2/3*DBP). |
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
|
Change From Baseline in Pulse Rate (PR)
Time Frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
For participants enrolled in Group A cohorts, pulse rate was initially assessed every 2 hours for up to 6 hours after the end of infusion. Following implementation of Protocol Amendment 3, the assessment frequency was increased to hourly only for participants undergoing RHC. |
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (first 8 hours, second 8 hours, third 8 hours), Day 3 (first 8 hours, second 8 hours, third 8 hours), Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
|
Fold Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
Time Frame: Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
NT-proBNP is a clinical biomarker of heart failure. Coefficient of Variation for Fold Change from Baseline was computed as (standard deviation of the natural log-scale of the respective variable) *100. Fold Change from Baseline is the ratio of Post-Baseline to Baseline, and it is assumed to follow a lognormal distribution. Per the study design, only some participants had a Day 4/Day 5 visit. Therefore, NT-proBNP data were not collected at this time point for all participants. |
Baseline, Day 1 (2 hours, 4 hours, and 6 hours post end of infusion), Day 2 (24 hours post end of infusion), Day 3, Day 4, Day 5, Day 8, Day 15, Day 22, Day 36, Day 57, Day 78, Day 99, Day 126
|
|
Peak Concentration (Cmax) of REGN5381 in Serum
Time Frame: Up to Day 126
|
Up to Day 126
|
|
|
Area Under the Concentration-time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) of REGN5381 in Serum
Time Frame: Up to Day 126
|
Up to Day 126
|
|
|
Number of Participants With Anti-drug Antibodies (ADA)
Time Frame: Baseline up to Day 126
|
The ADA status of each participant was classified as one of the following:
|
Baseline up to Day 126
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R5381-HF-2159
- 2021-006337-19 (EudraCT Number)
- 2023 (U.S. NIH Grant/Contract)
- 2023-506674-13-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.